logo
ResearchBunny Logo
The economic costs of precision medicine for clinical translational research among children with high-risk cancer

Medicine and Health

The economic costs of precision medicine for clinical translational research among children with high-risk cancer

C. E. L. Owens, O. Tan, et al.

This groundbreaking Australian study explores the economics of precision medicine in high-risk childhood cancers through the Zero Childhood Cancer Precision Medicine Programme. Discover the costs associated with genomic and preclinical testing, providing vital data for the future of pediatric oncology. Researchers include Christopher E. L. Owens, Owen Tan, Joice Kuroiwa-Trzmielina, and others.

00:00
00:00
Playback language: English
Abstract
This Australian study systematically measures the cost of using precision medicine in high-risk childhood cancers through the Zero Childhood Cancer Precision Medicine Programme. Costs included genomic and preclinical testing, totaling $12,743 per patient for access, $14,262 per molecular cause identification, and $21,769 per MTB recommendation. These findings provide crucial economic data for implementing precision medicine in pediatric oncology.
Publisher
npj Precision Oncology
Published On
Oct 05, 2024
Authors
Christopher E. L. Owens, Owen Tan, Joice Kuroiwa-Trzmielina, Rupendra N. Shrestha, Tracey O’Brien, Vanessa Tyrrell, Deborah J. Schofield
Tags
precision medicine
childhood cancer
genomic testing
pediatric oncology
economic analysis
Zero Childhood Cancer Programme
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny